Staar Surgical Co STAA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if STAA is a good fit for your portfolio.
News
-
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
-
STAAR Surgical to Report First Quarter Results on May 7, 2024
-
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
-
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024
-
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
-
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
-
STAAR Surgical to Participate in Two Upcoming Investor Conferences
-
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results
Trading Information
- Previous Close Price
- $44.69
- Day Range
- $44.38–45.78
- 52-Week Range
- $26.66–73.03
- Bid/Ask
- $45.48 / $45.54
- Market Cap
- $2.24 Bil
- Volume/Avg
- 414,118 / 716,802
Key Statistics
- Price/Earnings (Normalized)
- 42.97
- Price/Sales
- 6.85
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.10%
Company Profile
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,115
- Website
- https://www.staar.com
Comparables
Valuation
Metric
|
STAA
|
RXST
|
SGHT
|
---|---|---|---|
Price/Earnings (Normalized) | 42.97 | — | — |
Price/Book Value | 5.66 | 12.78 | 2.28 |
Price/Sales | 6.85 | 21.93 | 3.35 |
Price/Cash Flow | 39.85 | — | — |
Price/Earnings
STAA
RXST
SGHT
Financial Strength
Metric
|
STAA
|
RXST
|
SGHT
|
---|---|---|---|
Quick Ratio | 4.90 | 7.05 | 12.44 |
Current Ratio | 5.62 | 8.06 | 13.29 |
Interest Coverage | — | −15.68 | −9.25 |
Quick Ratio
STAA
RXST
SGHT
Profitability
Metric
|
STAA
|
RXST
|
SGHT
|
---|---|---|---|
Return on Assets (Normalized) | 8.13% | −17.04% | −23.43% |
Return on Equity (Normalized) | 10.15% | −21.78% | −31.87% |
Return on Invested Capital (Normalized) | 8.15% | −20.20% | −22.96% |
Return on Assets
STAA
RXST
SGHT
Medical Instruments & Supplies Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ISRG
| Intuitive Surgical Inc | Xlxphglfw | Ylqjy | $131.8 Bil | |
BDX
| Becton Dickinson & Co | Xpmtdncpg | Hvybtc | $67.5 Bil | |
ALC
| Alcon Inc | Cndkwlkfp | Hdxyrlt | $38.1 Bil | |
RMD
| ResMed Inc | Zqqvtbrtr | Jlfvvhm | $31.6 Bil | |
CLPBY
| Coloplast A/S ADR | Vfngbcdfrn | Rclx | $26.9 Bil | |
WST
| West Pharmaceutical Services Inc | Zflllkffx | Hkrst | $26.6 Bil | |
BAX
| Baxter International Inc | Vlshwqhn | Rjvvgw | $20.5 Bil | |
HOLX
| Hologic Inc | Dcrlltxq | Fhknjv | $17.9 Bil | |
COO
| The Cooper Companies Inc | Cnzxqqfr | Qqntzhq | $17.8 Bil | |
TFX
| Teleflex Inc | Ydgp | Ggqd | $10.0 Bil |